Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Arbutus Biopharma Cp (ABUS)

Arbutus Biopharma Cp (ABUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 490,013
  • Shares Outstanding, K 179,492
  • Annual Sales, $ 18,140 K
  • Annual Income, $ -72,850 K
  • 60-Month Beta 2.03
  • Price/Sales 27.51
  • Price/Cash Flow N/A
  • Price/Book 4.62
Trade ABUS with:

Options Overview Details

View History
  • Implied Volatility 43.17% ( -14.76%)
  • Historical Volatility 54.97%
  • IV Percentile 9%
  • IV Rank 4.05%
  • IV High 398.63% on 06/29/23
  • IV Low 28.16% on 05/25/23
  • Put/Call Vol Ratio 0.21
  • Today's Volume 204
  • Volume Avg (30-Day) 1,469
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 75,616
  • Open Int (30-Day) 66,449

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.10
  • Number of Estimates 2
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.10
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.30 +18.26%
on 04/03/24
3.29 -17.33%
on 04/05/24
+0.22 (+8.80%)
since 03/19/24
3-Month
2.27 +20.09%
on 02/02/24
3.29 -17.33%
on 04/05/24
+0.36 (+15.25%)
since 01/19/24
52-Week
1.69 +60.95%
on 10/24/23
3.29 -17.33%
on 04/05/24
-0.28 (-9.33%)
since 04/19/23

Most Recent Stories

More News
Arbutus: Q3 Earnings Snapshot

Arbutus: Q3 Earnings Snapshot

ABUS : 2.72 (-0.37%)
3 Stocks to Buy For the COVID Resurgence

The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting

MRNA : 101.41 (-0.58%)
NVAX : 3.97 (+2.06%)
PFE : 26.00 (+2.40%)
ALNY : 144.41 (-0.52%)
ABUS : 2.72 (-0.37%)
BNTX : 86.81 (+0.74%)
CVAC : 2.44 (unch)
LGF-A : N/A (N/A)
Arbutus: Q2 Earnings Snapshot

Arbutus: Q2 Earnings Snapshot

ABUS : 2.72 (-0.37%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arbutus Biopharma Corporation ("Arbutus" or the "Company") (NASDAQ: ABUS). Such...

ABUS : 2.72 (-0.37%)
Arbutus (ABUS) Upgraded to Buy: Here's Why

Arbutus (ABUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ABUS : 2.72 (-0.37%)
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

Here is how Arbutus Biopharma (ABUS) and Hologic (HOLX) have performed compared to their sector so far this year.

ABUS : 2.72 (-0.37%)
HOLX : 75.38 (+0.37%)
Arbutus: Q1 Earnings Snapshot

Arbutus: Q1 Earnings Snapshot

ABUS : 2.72 (-0.37%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arbutus Biopharma Corporation ("Arbutus" or the "Company") (NASDAQ: ABUS). Such...

ABUS : 2.72 (-0.37%)
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 33.56% and 13.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

SRPT : 115.62 (-0.80%)
ABUS : 2.72 (-0.37%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arbutus Biopharma Corporation ("Arbutus" or the "Company") (NASDAQ: ABUS). Such...

ABUS : 2.72 (-0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly...

See More

Key Turning Points

3rd Resistance Point 2.96
2nd Resistance Point 2.89
1st Resistance Point 2.80
Last Price 2.72
1st Support Level 2.64
2nd Support Level 2.57
3rd Support Level 2.48

See More

52-Week High 3.29
Last Price 2.72
Fibonacci 61.8% 2.68
Fibonacci 50% 2.49
Fibonacci 38.2% 2.30
52-Week Low 1.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar